Anavex Life Sciences Corp. (NASDAQ: AVXL) is a Healthcare company (Biotechnology) with a market capitalization of $69M. The Maz Rating grades it against the other companies in its sector.
Anavex Life Sciences Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.74, Anavex Life Sciences Corp. trades at 0.6x book value, with an EV/EBITDA of 4.7. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -11.4%, return on invested capital of -15.4% and a free cash flow yield of -49.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 15.62. Over the past 52 weeks the share price ranged from $0.71 to $5.36, with a beta of 1.25.
Anavex Life Sciences Corp. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 11 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of June 2026, Anavex Life Sciences Corp. (AVXL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 64.1% / 30% · Interest income / Revenue 107200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 64.1% / 33% · Receivables / Mkt Cap (36m) 0.54% / 49% · Interest income / Revenue 107200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 64.1% / 33.33% · Receivables / Mkt Cap (24m) 0.54% / 33.33% · Interest income / Revenue 107200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.8% / 33.33% · Receivables / Avg Assets (4Q) 0.74% / 33.33% · Interest income / Revenue 107200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.5% / 33.33% · (Cash+Recv) / Total Assets 99.3% / 33.33% · Interest income / Revenue 107200000.0% / 5% | Fail |
No. As of June 2026, Anavex Life Sciences Corp. (AVXL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Anavex Life Sciences Corp. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 107200000.0% of each dividend: Anavex Life Sciences Corp.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated June 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.